Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PX'Therapeutics
Grenoble, Auvergne-Rhône-Alpes, France
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
PX'Therapeutics was a leading French CRO/CDMO specializing in the development, engineering, process development, and GMP bioproduction of recombinant proteins—including monoclonal antibodies—for research through clinical use. It supported over 160 clients globally with expertise spanning early-stage research to clinical-grade manufacturing. In July 2019, it merged with Promise Advanced Proteomics under the Aguettant group to form Promise Proteomics. Notable projects included production of atexakin alfa for Relief Therapeutics targeting peripheral diabetic neuropathy and R&D programs such as OM-RCA–001 for kidney neoplasms.
- Therapeutic areas
- OncologyEndocrinologyInfectious Diseases
- Modalities
- Recombinant proteinMonoclonal antibodyAntibody fragmentCytokine
- Industry
- Contract Research Organization
02
Partnerships
Relief Therapeutics Holding AG
Beyond the preview
Go deeper on PX'Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PX'Therapeutics.